Scilex Holding Company Overview
Pro stress-test →Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company addresses the critical pain management market with novel formulations designed to reduce reliance on opioid therapies.
Strategic Profile
Pro stress-test →The company's lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN). The company develops three product candidates, including SP-102 (dexamethasone sodium phosphate viscous gel - SEMDEXA), SP-103 (lidocaine topical system) 5.4%, and SP-104 (low-dose naltrexone hydrochloride delayed-release capsules), positioning Scilex as a comprehensive non-opioid pain management player with expanding clinical pipeline.
Competitive Landscape
Pro stress-test →Scilex operates in the non-opioid pain management sector competing against larger pharmaceutical companies and emerging biotech firms. Key competitive areas include topical lidocaine products (against established players like Endo Pharmaceuticals), novel injectable formulations (SP-102 competing in epidural corticosteroid space), and low-dose naltrexone alternatives (fibromyalgia treatment). The company's strategy emphasizes FDA-approved, revenue-generating products with clinical-stage pipeline advancement.
Industry Context
Scilex Holding Company operates in Biopharmaceutical/Non-Opioid Pain Management.
Key facts
Founded: Not specified · Headquarters: Palo Alto, California · Employees: Not available · Revenue: Not disclosed · Market cap: $48.33M